Abemaciclib (Verzenios®). HTA ID: 20033

Assessment Status Rapid Review Complete
HTA ID 20033
Drug Abemaciclib
Brand Verzenios®
Indication For the treatment of women with hormone receptor positive , human epidermal growth factor receptor 2 negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.
Assessment Process
Rapid review commissioned 06/07/2020
Rapid review completed 27/08/2020
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of abemaciclib (Verzenios®) compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.